Discussion around statin discontinuation in older adults and patients with wasting diseases

Journal of Cachexia, Sarcopenia and Muscle

Volumn 7, Issue 4, 2016, Pages 396-399

  Banach, Maciej ^a   Serban, Maria Corina ^b,c  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CLINICAL TRIAL (TOPIC); DRUG WITHDRAWAL; EDITORIAL; GERIATRIC PATIENT; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TERMINALLY ILL PATIENT; WASTING SYNDROME;

EID: 84959300362     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12109     Document Type: Editorial

References (31)

1. Stepien M, Banach M, Mikhailidis DP, Gluba A, Kjeldsen SE, Rysz J. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 2009;25:1995–2005.
2. Hobbs FD, Banach M, Mikhailidis DP, Malhotra A, Capewell S. Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. BMC Med 2016;14:4.
3. Grundy SM. Statin discontinuation and intolerance: the challenge of lifelong therapy. Ann Intern Med 2013;158:562–563.
4. Serban MC, Banach M, Mikhailidis DP. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Expert Opin Pharmacother 2016;doi:10.1517/14656566.2016.1118055.
5. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387–2397.
6. Banach M, Aronow WS, Serban MC, Rysz J, Voroneanu L, Covic A. Lipids, blood pressure and kidney update 2015. Lipids Health Dis 2015;14:167.
7. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889–2934.
8. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015;11:1–23.
9. Anker MS, von Haehling S, Springer J, Banach M, Anker SD. Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. Int J Cardiol 2013;162:73–76.
10. Banach M, Malodobra-Mazur M, Gluba A, Katsiki N, Rysz J, Dobrzyn A. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des 2013;19:4904–4912.
11. Banach M, Serban C, Sahebkar A, Mikhailidis DP, Ursoniu S, Ray KK, et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med 2015;13:229.
12. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013;158:526–534.
13. Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metabol Cardiovasc Dis 2013;23:871–875.
14. Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol 2013;7:472–483.
15. Club AJ. Statins do not increase minor or serious symptomatic adverse events in placebo-controlled trials. Ann Intern Med 2014;161:JC3.
16. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014;21:464–474.
17. Golomb BA. Misinterpretation of trial evidence on statin adverse effects may harm patients. Eur J Prev Cardiol 2015;22:492–493.
18. Zhang H, Plutzky J, Skentzos S. Statins often tolerated after supposed statin-related event. Ann Intern Med 2013;158:526–534.
19. Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, et al. Lipid and Blood Pressure Meta-analysis Collaboration Group. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015;90:24–34.
20. Banach M, Aronow WS, Serban C, Sahabkar A, Rysz J, Voroneanu L, et al. Lipids, blood pressure and kidney update 2014. Pharmacol Res 2015;95–96:111–125.
21. Aronow WS. Lipid-lowering therapy in older persons. Arch Med Sci 2015;11:43–56.
22. Szadkowska I, Stanczyk A, Aronow WS, Kowalski J, Pawlicki L, Ahmed A, et al. Statin therapy in the elderly: a review. Arch Gerontol Geriatr 2010;50:114–118.
23. Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Ageing 2010;39:674–680.
24. th ed. Boca Raton: London, New York, CRC press; 2013. p67–103.
25. Lee DS, Markwardt S, Goeres L, Lee CG, Eckstrom E, Williams C, et al. Statins and physical activity in older men: the osteoporotic fractures in men study. JAMA Intern Med 2014;174:1263–1270.
26. Kutner JS, Blatchford PJ, Taylor DH Jr, Ritchie CS, Bull JH, Fairclough DL, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med 2015;175:691–700.
27. Geijteman ECT, Tiemeier H, van Gelder T. Selecting the optimal design for drug discontinuation trials in a setting of advanced, life-limiting illness. JAMA Intern Med 2015;175:1724–1725.
28. Mody P, Nguyen OK. Selecting the optimal design for drug discontinuation trials in a setting of advanced, life-limiting illness. JAMA Intern Med 2015;175:1725.
29. Colantonio LD, Bittner V, Reynolds K, Levitan EB, Rosenson RS, Banach M, et al. Association of serum lipids and coronary heart disease in contemporary observational studies. Circulation 2016;133:256–264.
30. Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J 2016;doi:10.1093/eurheartj/ehv641.
31. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015. J Cachexia Sarcopenia Muscle 2015;4:315–316.